Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) agreed to acquire additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. (SZSE:002393) for CNY 87.8 million on September 11, 2023. Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) entered into the Equity Transfer Agreement to acquire additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. (SZSE:002393) for CNY 87.8 million on October 10, 2023. The consideration will be financed through internal resources of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited.

As of August 31, 2023, Tianjin Pharmaceutical Group Finance Co., Ltd reported total assets of CNY 3.9 billion and net assets of CNY 590 million. The deal has been approved by board of directors of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited.